WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317110

CAS#: 163706-06-7

Description: Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.

Price and Availability


Ask price

Ask price

Ask price

Cangrelor, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 317110
Name: Cangrelor
CAS#: 163706-06-7
Chemical Formula: C17H25Cl2F3N5O12P3S2
Exact Mass: 774.94831
Molecular Weight: 774.37
Elemental Analysis: C, 26.30; H, 3.25; Cl, 9.13; F, 7.34; N, 9.02; O, 24.73; P, 11.97; S, 8.26

Synonym: AR-C69931MX; AR C69931MX; ARC69931MX; Cangrelor. Trade name: Kengreal (US); Kengrexal (Europe)

IUPAC/Chemical Name: (dichloro((((((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic acid


InChi Code: InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1

SMILES Code: CSCCNC1=NC(=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)SCCC(F)(F)F

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Judge HM, Buckland RJ, Jakubowski JA, Storey RF. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y(12) receptors in vitro. Platelets. 2015 Aug 13:1-5. [Epub ahead of print] PubMed PMID: 26270719.

2: Keating GM. Cangrelor: A Review in Percutaneous Coronary Intervention. Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3. PubMed PMID: 26201463.

3: Traynor K. Cangrelor approved for use during coronary angioplasty. Am J Health Syst Pharm. 2015 Aug 1;72(15):1254. doi: 10.2146/news150049. PubMed PMID: 26195642.

4: Bell RM, Sivaraman V, Kunuthur SP, Cohen MV, Downey JM, Yellon DM. Cardioprotective Properties of the Platelet P2Y(12) Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood. Cardiovasc Drugs Ther. 2015 Jul 16. [Epub ahead of print] PubMed PMID: 26179955.

5: Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis. 2015 Oct;40(3):317-22. doi: 10.1007/s11239-015-1233-3. PubMed PMID: 26024789.

6: Tang Y, Zhang YC, Chen Y, Xiang Y. Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials. Int J Clin Exp Med. 2015 Jan 15;8(1):800-8. eCollection 2015. PubMed PMID: 25785060; PubMed Central PMCID: PMC4358515.

7: Lhermusier T, Baker NC, Waksman R. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor. Am J Cardiol. 2015 Apr 15;115(8):1154-61. doi: 10.1016/j.amjcard.2015.01.551. Epub 2015 Feb 3. Review. PubMed PMID: 25728646.

8: Tamborini Permunian E, Riva N, Guasti L, Squizzato A. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):625-37. doi: 10.1517/17425255.2015.1021330. Epub 2015 Mar 1. PubMed PMID: 25728292.

9: Montalescot G, Helft G. The arranged marriage of cangrelor and bivalirudin. JACC Cardiovasc Interv. 2015 Mar;8(3):434-5. doi: 10.1016/j.jcin.2015.01.004. Epub 2015 Feb 18. PubMed PMID: 25703891.

10: White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015 Mar;8(3):424-33. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18. PubMed PMID: 25703887.

11: Waite LH, Phan YL, Spinler SA. Cangrelor: a novel intravenous antiplatelet agent with a questionable future. Pharmacotherapy. 2014 Oct;34(10):1061-76. doi: 10.1002/phar.1471. Epub 2014 Aug 13. Review. PubMed PMID: 25123696.

12: Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015 Jan;26(1):42-8. doi: 10.1097/MCA.0000000000000158. PubMed PMID: 25089928.

13: Bonadei I, Sciatti E, Vizzardi E, D'Aloia A, Raddino R, Metra M. New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Recent Pat Cardiovasc Drug Discov. 2014;9(1):22-7. PubMed PMID: 24915974.

14: Marino M, Rizzotti D, Leonardi S. Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX). Curr Cardiol Rep. 2014;16(6):493. doi: 10.1007/s11886-014-0493-4. Review. PubMed PMID: 24879371.

15: Oestreich JH, Dobesh PP. Cangrelor for treatment during percutaneous coronary intervention. Future Cardiol. 2014 Mar;10(2):201-13. doi: 10.2217/fca.13.108. PubMed PMID: 24762247.

16: Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014 Apr;7(4):435-42. doi: 10.1016/j.jcin.2013.08.017. Epub 2014 Mar 19. PubMed PMID: 24656538.

17: Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc Interv. 2014 Apr;7(4):426-34. doi: 10.1016/j.jcin.2013.11.019. Epub 2014 Mar 13. PubMed PMID: 24630878.

18: Walsh JA 3rd, Price MJ. Cangrelor for treatment of arterial thrombosis. Expert Opin Pharmacother. 2014 Mar;15(4):565-72. doi: 10.1517/14656566.2014.882319. Epub 2014 Jan 30. Review. PubMed PMID: 24479981.

19: Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, Jeong YH, Fabiszak T, Andruszkiewicz A, Gurbel PA. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014 May;30(5):813-28. doi: 10.1185/03007995.2014.880050. Epub 2014 Jan 24. Review. PubMed PMID: 24393016.

20: Serebruany VL, Pokov AN, Fortmann SD, DiNicolantonio JJ. Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge. Thromb Haemost. 2014 Jan;111(1):3-7. doi: 10.1160/TH13-08-0631. Epub 2013 Nov 28. PubMed PMID: 24285121.